GRACE

cancergrace.org

 

GRACE
Avatar

Current Standards and Novel Therapies for Sensitizing Mutations in EGFRm NSCLC

By GRACE FEATURING Jack West
By GRACE FEATURING Jack West
49 views
April 20, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
2021 Targeted Therapies Patient Forum
13:32
CancerGRACE

Targeted Therapies in Oligo-Metastatic NSCLC

Feat. T. Leal
17:04
CancerGRACE

Genotype Directed Therapies: Their Role in Earlier Stage NSCLC

Feat. Z. Piotrowska
15:19
GRACE

The Role of Chemotherapy in Driver Positive NSCLC

Feat. J. Weiss
05:59
GRACE

Will There Ever be an Opportunity to Use TKI + IO Together in NSCLC?

Feat. J. West, Z. Piotrowska, B. Levy
08:30
CancerGRACE

Is There a Role for Chemo + IO in NSCLC With EGFR Mutations and When…

Feat. J. West, Z. Piotrowska, B. Levy
09:16
GRACE

Is There a Role for Single Agent Immunotherapy Ever in Driver Mutati…

Feat. J. West, Z. Piotrowska, B. Levy
22:23
GRACE

Targeted Therapy for Rare NSCLC Drivers: NTRK, RET, and HER2

Feat. M. Das
21:10
GRACE

Tissue Genotyping: Challenges and Best Practices - Optimal NGS Platf…

Feat. J. Weiss
14:32
GRACE

Current Standards and Novel Therapies for Sensitizing Mutations in E…

Feat. J. West
04:43
GRACE

Common Mutations Changing to Different Drivers: Should NSCLC Be Biop…

Feat. J. West, J. Gainor
20:47
GRACE

ALK Therapies in NSCLC: Which One Comes First and How Do We Sequence

Feat. C. Kim
19:32
GRACE

ROS1 Therapies in NSCLC: Current and Emerging Treatment Options

Feat. J. Lin
04:06
CancerGRACE

NSCLC Q&A: After CRT, What Is Recommended for 2L Treatment and T…

Feat. J. Lin, C. Kim
16:50
GRACE

KRAS Directed Therapies in NSCLC: A New Horizon

Feat. L. Bazhenova
16:35
GRACE

Liquid Biopsies in NSCLC: Current Applications

Feat. J. Thompson